Trial Profile
A Phase III trial of Pimavanserin as an adjunctive treatment for Major Depressive Disorder
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2018
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 04 Dec 2018 New trial record
- 31 Oct 2018 According to an Acadia Pharmaceuticals media release, the company is looking forward to meet with the FDA and initiate this trial in the first half of 2019.